Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:130470007" >
The HELIOS trial pr...
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia
-
Hallek, M (författare)
-
Kay, NE (författare)
-
- Osterborg, A (författare)
- Karolinska Institutet
-
visa fler...
-
Chanan-Khan, AA (författare)
-
Mahler, M (författare)
-
Salman, M (författare)
-
Wan, Y (författare)
-
Sun, S (författare)
-
Zhuang, SH (författare)
-
Howes, A (författare)
-
visa färre...
-
(creator_code:org_t)
- Future Medicine Ltd, 2015
- 2015
- Engelska.
-
Ingår i: Future oncology (London, England). - : Future Medicine Ltd. - 1744-8301 .- 1479-6694. ; 11:1, s. 51-59
- Relaterad länk:
-
https://www.futureme...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- ABSTRACT Ibrutinib is an orally administered, covalent inhibitor of Bruton's tyrosine kinase with activity in B-cell malignancies based on Phase I/II studies. We describe the design and rationale for the Phase III HELIOS trial (trial registration: EudraCT No. 2012-000600-15; UTN No. U1111-1135-3745) investigating whether ibrutinib added to bendamustine and rituximab (BR) provides benefits over BR alone in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Eligible patients must have relapsed/refractory disease measurable on CT scan and meet ≥1 International Workshop on Chronic Lymphocytic Leukemia criterion for requiring treatment; patients with del(17p) are excluded. All patients receive BR (maximum six cycles) as background therapy and are randomized 1:1 to placebo or ibrutinib 420 mg/day. Treatment with ibrutinib or placebo will start concomitantly with BR and continue until disease progression or unacceptable toxicity. The primary end point is progression-free survival. Secondary end points include safety, objective response rate, overall survival, rate of minimal residual disease-negative remissions, and patient-reported outcomes. Tumor response will be assessed using the International Workshop on Chronic Lymphocytic Leukemia guidelines.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hallek, M
-
Kay, NE
-
Osterborg, A
-
Chanan-Khan, AA
-
Mahler, M
-
Salman, M
-
visa fler...
-
Wan, Y
-
Sun, S
-
Zhuang, SH
-
Howes, A
-
visa färre...
- Artiklar i publikationen
-
Future oncology ...
- Av lärosätet
-
Karolinska Institutet